Ads
related to: long acting bronchodilator inhaler- Adverse Reactions
Learn About The Adverse Reactions
Of This Daily COPD Treatment.
- Samples & Savings
Request Samples For Your Practice
Daily Triple Therapy COPD Option.
- Dosing Information
HCPs: See The Dosing Information Of
This Once-Daily COPD Inhaler.
- Formulary Coverage
See If Your Patients Are Covered
With This Daily COPD Treatment.
- Triple Therapy Delivery
View The Delivery Methods Of This
Daily Triple Therapy COPD Option.
- Resources & Information
Access Resources & Important Info
For A COPD Therapy Here.
- Adverse Reactions
Search results
Results From The WOW.Com Content Network
Short-acting medications provide quick or "rescue" relief from acute bronchoconstriction. Long-acting bronchodilators help to control and prevent symptoms. The three types of prescription bronchodilating drugs are beta-2 adrenergic agonists (short- and long-acting), anticholinergics (short- and long-acting), and theophylline (long-acting).
Formoterol, also known as eformoterol, is a long-acting β 2 agonist (LABA) used as a bronchodilator in the management of asthma and chronic obstructive pulmonary disease (COPD). Formoterol has an extended duration of action (up to 12 h) compared to short-acting β 2 agonists such as salbutamol (albuterol), which are effective for 4 h to 6 h.
Tiotropium bromide, sold under the brand name Spiriva among others, is a long-acting bronchodilator (LAMA: long acting muscarinic antagonist) used in the management of chronic obstructive pulmonary disease (COPD) and asthma.
Salmeterol is a long-acting β 2 adrenergic receptor agonist (LABA) used in the maintenance and prevention of asthma symptoms and maintenance of chronic obstructive pulmonary disease (COPD) symptoms. [2] Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness.
Olodaterol is a once-daily maintenance bronchodilator treatment of airflow obstruction in people with COPD. [3] While it appears to reduce COPD exacerbations it does not appear to alter the speed at which a person's lungs worsen or alter their life expectancy. [3] As of December 2013, olodaterol is not approved as a treatment of asthma.
On 18 November 2005, the U.S. Food and Drug Administration (FDA) alerted healthcare professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing in some people, and requested that manufacturers update warnings in their existing product labeling.